Clinical Trials Browser

Completed × Interventional × selinexor × Clear all

NCT03555422 2026-04-13

ENGOT-EN5

Phase 3 Completed

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT02069730 2026-01-08

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Phase NA Completed

Neoplasm Metastasis, Neoplasms, Recurrence, Salivary Gland Neoplasms

NCT02199665 2025-11-03

SINE

Phase 1 Completed

Multiple Myeloma

NCT04850755 2025-09-25

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Phase 1 Completed

Advance Solid Malignancies

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Phase 1 Completed

34 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04811196 2025-05-29

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

Phase 1 Completed

GynecologicSarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Neurofibrosarcoma

NCT04256707 2025-03-19

SPRINT

Phase 1/2 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

Multiple Myeloma

NCT03992339 2025-02-07

SEARCH

Phase 2 Completed

60 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse

NCT02323880 2025-01-14

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Phase 1 Completed

59 enrolled 20 charts

Astrocytoma, Brain Neoplasms, Glioma, Lymphoma, Central Nervous System Neoplasms

NCT03955783 2024-10-26

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Phase 1 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT06212596 2024-01-19

MUKtwelve

Phase 2 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01896505 2024-01-08

A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma

Phase 1 Completed

54 enrolled 28 charts

Bone Neoplasms, Sarcoma

NCT02178436 2023-11-07

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Phase 1/2 Completed

15 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04534725 2023-08-24

C-SMART

Phase 3 Completed

COVID-19, Neoplasms

NCT02299518 2023-06-15

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT02120222 2023-04-04

KPT-330

Phase 1 Completed

Melanoma

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Phase 1 Completed

192 enrolled 29 charts

CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

NCT02025985 2023-01-26

SIGN

Phase 2 Completed

116 enrolled 21 charts

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02088541 2023-01-26

SOPRA

Phase 2 Completed

317 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02606461 2023-01-23

SEAL

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02780609 2022-11-04

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Phase 1/2 Completed

22 enrolled 16 charts

Multiple Myeloma

NCT02403310 2022-10-03

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Phase 1 Completed

Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Leukemia, Myeloid, Acute

NCT02471911 2022-04-12

KPT-330+RICE

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

NCT03042819 2021-12-09

Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas

Phase 1 Completed

Sarcoma

NCT02741388 2021-12-07

SELINDA

Phase 1 Completed

Lymphoma, Lymphoma, B-Cell

NCT02249091 2021-08-25

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 2 Completed

42 enrolled 16 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02485535 2021-05-13

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03212937 2021-04-28

Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma

Phase 1 Completed

Lymphoma, T-Cell, Peripheral

NCT02269293 2021-04-23

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Phase 1 Completed

Ovarian Neoplasms, Endometrial Neoplasms

NCT02831686 2020-11-24

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Phase 1 Completed

Multiple Myeloma

NCT02402764 2020-09-11

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Phase 2 Completed

10 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02078349 2020-09-10

Phase I Study of KPT330 in Asian Patients

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT03661515 2020-05-20

FLAGINEXOR

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02573363 2020-04-08

Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02530476 2020-03-31

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Phase 1/2 Completed

17 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02212561 2020-03-26

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02416908 2020-03-13

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

40 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02250885 2019-09-17

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Phase 2 Completed

Carcinoma, Neuroendocrine

NCT02093403 2017-12-08

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute